Multiple myeloma is the second most common hematological malignancy in the United States, and it’s increasing in incidence. An estimated 32,110 new cases will be diagnosed in 2019, with nearly 13,000 deaths caused by the disease. Certain patients have what is known as high-risk multiple myeloma (HRMM), meaning they have distinct molecular features that lead to more rapid progression and poorer outcomes.
The High-Risk Multiple Myeloma...
A randomized Phase III clinical trial combining two common chemotherapy agents as a pre-stem cell transplant treatment at The University of...
Recently approved targeted and immunotherapy drugs are helping patients diagnosed with follicular lymphoma live longer. Knowing the available...
Natural killer cells sound menacing, but they play a friendly role in keeping us healthy. And they might do much more in stopping cancer.
After years of diligent, groundbreaking research, MD Anderson physician-scientists are putting natural killer cells – NK cells for short – to work in a series of clinical trials for a variety of cancers through the cancer center’s Moon Shots Program™.
“These white...
MD Anderson’s Moon Shots Program has expanded its targets, adding some of the most intractable cancers to its campaign to more rapidly convert...
The costs associated with cancer drug prices have risen dramatically over the past fifteen years, which concerns many top oncologists. In...